Medicine
Dupixent 300 mg/2 mL injection
Dupixent 300 mg/2 mL injection is a prescription medicine containing Dupilumab for subcutaneous use, marketed by Sanofi-Aventis, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to…
Key facts
- Active ingredient (INN)
- Dupilumab
- Brand
- Dupixent
- Strength
- 300 mg/2 mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 2 syringes of 2 mL and 1 more
- Marketing authorisation holder
- Sanofi-Aventis
- Manufacturer
- Sanofi-Aventis
- Origin register
- US FDA, United States
- Storage
- Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. After removal from the refrigerator, DUPIXENT must be used within 14 days or discarded. Do NOT freeze. If necessary, DUPIXENT may be kept at room temperature up to 25°C (77°F) for a maximum of 14 days. Do not store above 25°C (77°F). Do NOT shake.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- D11AH05 Dupilumab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 28 March 2017
- Identifiers
- RxCUI 1876401, 1876406, 2099300 +5DailyMed set ID 595f437d-2729-40bb-9c62-c8ece1f82780NDC 0024-5914, 0024-5915Application BLA761055
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 2 syringe, glass in 1 carton / 2 mL in 1 syringe, glass | 0024-5914-01 | Sanofi-Aventis | 28 March 2017 |
| 2 syringe, glass in 1 carton / 2 mL in 1 syringe, glass | 0024-5914-02 | Sanofi-Aventis | 1 July 2018 |
| 2 syringe, glass in 1 carton / 2 mL in 1 syringe, glass | 0024-5915-02 | Sanofi-Aventis | 19 June 2020 |
| 2 syringe, glass in 1 carton / 2 mL in 1 syringe, glass | 0024-5915-20 | Sanofi-Aventis | 19 June 2020 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Dupilumab
Clinical summary
Dupilumab is an interleukin-4 receptor alpha antagonist indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe AD, among other approved uses. It is available as injection for subcutaneous use. MedsAcross supplies Dupilumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about DupilumabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Dupixent prescribing information (Sanofi-Aventis) · U.S. National Library of Medicine, DailyMed
- Dupixent: European public assessment report (EPAR) · European Medicines Agency
Need Dupixent 300 mg/2 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.